Does the association of $^{18}$F-FDG uptake intensity and lesion topography reveal histological phenotype and tumor differentiation in esophageal cancer?

Abstract

In daily clinical practice, the esophageal squamous cell cancer (ESCC) is considered to be more $^{18}$F-FDG avid than adenocarcinoma (EAD). To date, the few studies concerning the existence of a real metabolic difference based on esophageal cancer (EC) histology, show divergent and not definitive results. A retrospective analysis of $^{18}$F-FDG PET/CT of 87 patients with ESCC and EAD was performed to investigate the role played by both histopathological subtype and tumor differentiation in the characterization of glucose metabolic profile of EC. Esophageal squamous cell cancer was well differentiated (WD) in 42 cases and poorly differentiated (PD) in 12 patients. Twenty-one of the 33 patients had WD EAD, while 12 had a PD EAD. The $^{18}$F-FDG maximal standardized uptake value ($SUV_{max}$) was determined for all lesions and used for inter and intra-group comparison. In ESCC, the $SUV_{max}$ ranged from 4 to 31 with a mean value of 16±6. In EAD, the $SUV_{max}$ ranged from 2 to 25 with a mean value of 10±6. A statistically significant difference ($P<0.0001$) was found between ESCC and EAD. According to histological classification and tumor differentiation, we obtained the following results: a) the $SUV_{max}$ values of WD ESCC and WD EAD were 17±5 (range:7-31) and 7±3 (range:2-12) respectively ($P<0.00001$), b) the $SUV_{max}$ values of PD ESCC and PD EAD were 11±4 (range:4-19) and 17±6 (range:7-25) respectively ($P<0.05$). Moreover, a statistically significant difference of $SUV_{max}$ values was found between WD and PD ESCC ($P<0.005$) as well as between WD and PD differentiated EAD ($P<0.0001$). In order to predict tumor histology (ESCC, EAD) from both $SUV_{max}$ and lesion location, a multivariate discriminant analysis was performed on the whole population with a resulting diagnostic accuracy equal to 82% ($P<0.00001$). In conclusion, we provide additional arguments about $^{18}$F-FDG uptake difference between ESCC and EAD as well as between poorly and well-differentiated forms of both EC histological subtypes.

Introduction

** means**

---

Alessio Imperiale1,2 MD, Sébastian Cimarelli3 MD, Cécile Brigand4 MD, Guillaume Faure5 MD, Gilles Karcher6 MD, Serge Rohr7 MD, David Atlani7 MD, Pierre Olivier8 MD

1. Service de Biophysique et de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
2. LINC, UMR 7237, UDS / CNRS, Strasbourg, France
3. Service de Médecine Nucléaire, CLRCC Leon Berard, Lyon, France
4. Service de Chirurgie Générale et Digestive, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
5. Service de Radiothérapie, Clinique Claude Bernard, Metz, France
6. Service de Biophysique et de Médecine Nucléaire, Hôpital de Brabois, Hôpitaux Universitaires de Nancy, Vandoeuvre Lès Nancy, France
7. Service de Radiothérapie, Hôpital Civil, Colmar, France

***

Keywords: Esophageal cancer - FDG PET - Esophageal adenocarcinoma - Esophageal squamous cell carcinoma - Tumor differentiation

Correspondence address:
Alessio Imperiale, MD
Service de Biophysique et de Médecine Nucléaire, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg 1, Avenue Molière, 67098 Strasbourg Cedex, France, Tel: +33388127552, Fax: +33388128121
Email: alessio.imperiale@chru-strasbourg.fr

Received:
5 September 2011
Accepted revised:
17 October 2011
Subjects and methods

We have performed a retrospective analysis of patients addressed to the Nuclear Medicine Department of both Strasbourg and Nancy University Hospitals for EC evaluation by PET/CT before any treatment.

Eligible patients were identified by "18F-FDG PET/CT databases according to the following inclusion criteria: a) either ESCC or EAD proved by biopsy, b) tumor stage from II to IV proved by either endoscopic ultrasound (EUS) or pathologic criteria according to the TNM system of the American Joint Committee on Cancer, c) availability of unequivocal pathological information about tumor differentiation: only well differentiated (WD) and poorly differentiated (PD) tumors were selected.

We have left out of our study the patients with: a) histological types of EC different from ESCC and EAD (i.e. leimyoma, gastrointestinal stromal tumor, small cell carcinoma), b) tumor stage 0 and I according to both clinical and pathological criteria, c) either ESCC or EAD moderately differentiated, and d) history of esophageal surgery, radiotherapy or chemotherapy before PET examination.

Discovery (General Electric, Milwaukee, USA) and Biograph Duo (Siemens, Knoxville, USA) PET/CT devices were used in Strasbourg and Nancy, respectively. To obtain a serum glucose level of less than 6.6mmol/L, the patient fasted for 6h before the intravenous injection of 5MBq/kg of "18F-FDG. Whole-body PET/CT acquisitions started 60min after tracer injection, including a head to mid thigh CT scan, followed by a 2-di-

Results

The clinical and 18F-FDG PET results are summarized in Table 1 and Table 2 respectively.

Table 1. Patient population clinical characteristics

<table>
<thead>
<tr>
<th>No</th>
<th>Sex</th>
<th>Pt age</th>
<th>Tumor location</th>
<th>T</th>
<th>T Diff</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(M / F)</td>
<td>mean±SD (range)</td>
<td>Up</td>
<td>Med</td>
<td>Low</td>
</tr>
<tr>
<td>ESCC</td>
<td>54</td>
<td>63±9 (49-82)</td>
<td>21</td>
<td>11</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EAD</td>
<td>33</td>
<td>62±11 (38-85)</td>
<td>1</td>
<td>21</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ESCC: esophageal squamous cell cancer; EAD: esophageal adenocarcinoma; Up: upper esophagus; Med: medial esophagus; Low: lower esophagus; LC: lower esophagus and cardia; T: tumor stage according to TNM classification [6]; T Diff: tumoral differentiation; WD: well differentiated; PD: poorly differentiated.

Table 2. "18F-FDG PET results (SUV_{max}) obtained from the analysis of the whole population

<table>
<thead>
<tr>
<th>No</th>
<th>WD EC</th>
<th>PD EC</th>
</tr>
</thead>
<tbody>
<tr>
<td>mean±SD</td>
<td>median</td>
<td>range</td>
</tr>
<tr>
<td>ESCC</td>
<td>17±5</td>
<td>16</td>
</tr>
<tr>
<td>EAD</td>
<td>7±3</td>
<td>6</td>
</tr>
</tbody>
</table>

P ESCC vs. EAD | < 0.00001 | < 0.05 |

ESCC: esophageal squamous cell cancer; EAD: esophageal adenocarcinoma; WD: well differentiated; PD: poorly differentiated; EC: esophageal cancer.
Among the eighty-seven patients selected for this study (68 men and 19 women; age: 63±10; age range: 38-85), fifty-four (62%) and thirty-three (38%) patients were found to be affected with ESCC and EAD respectively. Esophageal SCC was well differentiated in forty-two cases and poorly differentiated in the remaining twelve patients. Twenty-one of the 33 patients had well-differentiated EAD, while 12 had a poorly differentiated EAD. Esophageal SCC was located in the proximal, medial and distal part of the oesophagus in 21, 21 and 12 cases, respectively. On the other hand, EAD was detected in the proximal, medial and distal part of the oesophagus in 1, 2 and 30 patients. As for the T grade, 33, 51 and 3 esophageal lesions were graded as T2, T3 and T4 respectively.

All ESCC and EAD primary tumours were visualised on 18F-FDG PET/CT images (Fig. 1).

In the 54 examined ESCC, SUV<sub>max</sub> ranged from 4 to 31 with a mean value of 16±6. For all the EAD, SUV<sub>max</sub> ranged from 2 to 25 with a mean value of 10±6. A statistically significant difference (P<0.00001) was found between ESCC and EAD.

According to both histological classification and tumor differentiation (Fig. 2): a. The SUV<sub>max</sub> values of WD ESCC and EAD resulted as being equal to 17±5 (range: 7-31) and 7±3 (range: 2-12), respectively. A statistically significant difference was found between ESCC and EAD (P<0.0001). b. The SUV<sub>max</sub> values of PD ESCC and EAD resulted as being equal to 11±4 (range: 4-19) and 17±6 (range: 7-25), respectively. A statistically significant difference was found between ESCC and EAD (P<0.05). c. A statistically significant difference of SUV<sub>max</sub> values was found between WD and PD ESCC (P<0.005) as well as between WD and PD EAD (P<0.0001).

In order to predict tumor histology (ESCC, EAD) from both SUV<sub>max</sub> and lesion location (LOC: proximal, medial and distal part of the oesophagus), a multivariate discriminant analysis was performed on the whole population (87 patients). SUV<sub>max</sub> together with LOC correctly identified 43 of 54 (80%) ESCCs and 28 of 33 (85%) EAD with a global diagnostic accuracy of 82%, a sensitivity and specificity of 72% and 90%, respectively, an 85% positive predictive value, and an 80% negative predictive value (P<0.00001).

Discussion

The SUV index presents certain limitations that are mainly due to important sources of variability in its determination [6]. In spite of that, it is still considered as the reference index whenever a quantitative evaluation is needed for diagnosis, therapy evaluation or for the purpose of prognosis. A close correlation between the 18F-FDG uptake intensity and both the over expression of Glut-1 membrane transporters and the up-regulation of intracellular hexokinase (HK) has been previously assessed in EC [7-8]. In well-differentiated forms of lung and cervical cancer, the reduced Glut-1 and HK-II expression are directly responsible for a low 18F-FDG uptake [3-4]. It is then reasonable to suppose that cellular differentiation has a key role in the modulation of the 18F-FDG uptake also in EC.

In daily clinical practice, ESCC is considered to be more 18F-FDG avid than EAD, the 18F-FDG uptake variability of EAD appearing to be wider than that of the ESCC. But, to date, the few studies concerning the existence of a real metabolic difference based on EC histology, show divergent and not definitive results.

The first study reporting a systematic investigation about the influence of histopathologic subtype and EC grading on the 18F-FDG uptake was published by Mentzel et al (2003) [5]. These authors examined forty-six patients suffering from EC (28 ESCC and 18 EAD) by the pre-therapeutic 18F-FDG PET/CT technique and different degrees of tumoral differentiation. The SUV<sub>max</sub> was used for 18F-FDG tumor intensity evaluation. Both ESCC and EAD were characterized by an important intra-group variability in terms of SUV<sub>max</sub>. Although EAD showed a mean SUV<sub>max</sub> value that was moderately less than that of ESCC, the difference of uptake intensity was not statistically significant. Likewise, there was a slight but not relevant trend towards higher SUV<sub>max</sub> in more dedifferentiated cancer. Unfortunately, the size of all the examined subgroups was limited, particularly those related to tumoral differentiation, so making the interpretation of the statistical results both difficult and possibly not definitive. To explain
the molecular events responsible for the increased $^{18}$F-FDG uptake in EC, others [9] proposed a genetic model of esophageal cancer. Interestingly, in their preliminary results, the authors showed a significantly increased $^{18}$F-FDG uptake in ESCC compared to the EAD experimental model.

Our present study is focused on an accurately selected population. Indeed, in order to minimize the PET partial volume effect on SUV$_{\text{max}}$ estimation, tumor stage from II to IV was only considered, so excluding both tumor stage 0 and I. Moreover, in order to maximize the effect of differentiation on tumoral $^{18}$F-FDG uptake, we have not included any moderately differentiated ESCC or EAD. In spite of an important heterogeneity of SUV$_{\text{max}}$ values, the non-parametric statistical analysis applied to our data showed a significant difference between the SUV$_{\text{max}}$ of ESCC and that of EAD. Furthermore, the good global diagnostic accuracy (82%) when predicting tumor histology from both SUV$_{\text{max}}$ and lesion location, underlined the existence of different glucose metabolism between ESCC and EAD. The two histological EC subtypes were even more evidently discriminated by adding as a grouping factor the data regarding the tumor grading to the statistical analysis. In the EAD case, the SUV$_{\text{max}}$ was directly related to the tumoral dedifferentiation. Conversely, the more differentiated the ESCC was, the more important the $^{18}$F-FDG uptake intensity became, which agrees with the observations of others [10]. These authors investigated the expression of the neutral amino acid transporter ASCT1 and its potential correlation with the Glut-1 glucose transporter in forty-two resected EC. Interestingly, Glut-1 was expressed more often in the well differentiated ESCC than in the poorly differentiated one, representing a potential explication for our findings. Indeed, according to our results, the well differentiated ESCC were characterized from higher values of SUV$_{\text{max}}$ than the poorly differentiated one. The same authors also showed that significantly more EAD expressed ASCT1 than ESCC [10], suggesting different metabolic needs between these two tumor histological subtypes.

One of the major limitations of the present study, directly related to its retrospective nature, is the lack of Glut-1 and HK immunohistochemical quantification, which would have allowed a better understanding of the relationship between the tumoral pathophysiological mechanisms and SUV$_{\text{max}}$.

In conclusion, we provide additional arguments concerning the $^{18}$F-FDG uptake difference between ESCC and EAD as well as between poorly and well-differentiated forms of both EC histological subtypes. Just for common opinion, our results also suggest that poor differentiation is not necessarily matched with a high $^{18}$F-FDG uptake.

The authors declare that they have no conflicts of interest.

Bibliography